Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL

Jong Eun Yeon

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)

    Abstract

    The paradigm for the treatment of chronic hepatitis C (CHC) has been changed due to the development of direct acting antivirals (DAAs) of hepatitis C virus (HCV). The high sustained virologic response rate and ease of administration makes the DAAs approach ideal to contribute to the complete eradication of HCV. Currently, treatment options for individual patients vary depending on the genotype or subtype of HCV, presence or absence of liver cirrhosis, previous experience of antiviral treatment or resistance associated substitutions. Because of drug avalilability, cost-effectiveness, preference, compliance and greater possibility of desirable effects and presumed patient-important outcomes may vary between countries, treatment options for individual patients are different. The review focuses on the comparing the current treatment options for CHC in other continents with the 2017 Korea Association for the Study of the Liver guidelines.

    Original languageEnglish
    Pages (from-to)278-293
    Number of pages16
    JournalClinical and Molecular Hepatology
    Volume24
    Issue number3
    DOIs
    Publication statusPublished - 2018 Sep 1

    Keywords

    • Direct acting antiviral
    • Genotype
    • Hepatitis C virus
    • Liver cirrhosis
    • Resistance associated substitutions

    ASJC Scopus subject areas

    • Hepatology
    • Molecular Biology

    Fingerprint

    Dive into the research topics of 'Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL'. Together they form a unique fingerprint.

    Cite this